Differences between Prozac- and Zoloft
Contents
Prozac vs. sertraline[edit]
Prozac (fluoxetine) and Zoloft (sertraline) are medications in the selective serotonin reuptake inhibitor (SSRI) class. These drugs work by increasing the concentration of serotonin in the synaptic cleft by inhibiting its reabsorption into the presynaptic neuron. Although they share the same primary mechanism, they possess distinct chemical structures, half-lives, and FDA-approved clinical indications. Fluoxetine was the first SSRI to gain approval in the United States in 1987, while sertraline entered the market in 1991.
Comparison table[edit]
| Feature | Prozac (fluoxetine) | Zoloft (sertraline) |
|---|---|---|
| FDA approval year | 1987 | 1991 |
| Elimination half-life | 4–6 days (parent), 4–16 days (metabolite) | ~26 hours |
| Common starting dose | 20 mg daily | 50 mg daily |
| FDA approved for PTSD | No | Yes |
| FDA approved for bulimia | Yes | No |
| Common side effect profile | Activating (insomnia, anxiety) | Gastrointestinal (diarrhea, nausea) |
| Metabolism | CYP2D6, CYP3A4 inhibitor | Weak CYP2D6 inhibitor |
| Pregnancy category | C (Potential risk) | C (Potential risk) |
Pharmacokinetic differences[edit]
The primary distinction between these two medications involves their elimination half-life. Fluoxetine has a significantly longer half-life than other SSRIs. The parent drug persists for four to six days, and its active metabolite, norfluoxetine, remains in the body for up to sixteen days. This long duration reduces the risk of SSRI discontinuation syndrome if a patient misses a dose. Conversely, it requires a longer "washout" period before a patient can safely switch to other medications, such as monoamine oxidase inhibitors (MAOIs).
Sertraline has a shorter half-life of approximately 26 hours. It does not have active metabolites that persist as long as norfluoxetine. Because of this shorter duration, patients who abruptly stop taking sertraline are more likely to experience withdrawal symptoms, including dizziness, irritability, and sensory disturbances.
Clinical indications[edit]
The FDA has approved both drugs for major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and premenstrual dysphoric disorder (PMDD). However, their specific approved uses diverge for other conditions. Sertraline is specifically indicated for the treatment of post-traumatic stress disorder (PTSD) and social anxiety disorder. Fluoxetine is the only SSRI approved by the FDA for the treatment of bulimia nervosa.
In pediatric populations, fluoxetine is approved for depression in children aged eight and older. Sertraline's pediatric approval is limited to the treatment of OCD in children aged six and older.
Side effect profiles[edit]
Physicians often select between these agents based on their side effect tendencies. Fluoxetine is characterized as an "activating" SSRI. Patients frequently report increased energy, which can be beneficial for those with lethargic depression but may cause insomnia or jitteriness in those with baseline anxiety.
Sertraline is more frequently associated with gastrointestinal distress. Clinical trials showed a higher incidence of diarrhea and dyspepsia in patients taking sertraline compared to those taking other SSRIs. Sertraline has a lower potential for drug-drug interactions than fluoxetine because it is a weaker inhibitor of the CYP2D6 enzyme, which processes many other common medications.
